http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 17:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html si-local-file:///var/storage/secattach/20260310/26140940.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html si-local-file:///var/storage/secattach/20260310/26140940.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html si-local-file:///var/storage/secattach/20260310/26140940.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+CHEMEROW+DAVID+I./26140940.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html si-local-file:///var/storage/secattach/20260310/26140941.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html si-local-file:///var/storage/secattach/20260310/26140941.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html si-local-file:///var/storage/secattach/20260310/26140941.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+06++Filed+by%3A+Equels+Thomas+K/26140941.html Tue, 10 Mar 2026 17:57:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html si-local-file:///var/storage/secattach/20260306/26126649.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html Fri, 06 Mar 2026 17:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html si-local-file:///var/storage/secattach/20260306/26126649.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html Fri, 06 Mar 2026 17:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html si-local-file:///var/storage/secattach/20260306/26126649.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AIM+ImmunoTech+Inc.+++++++For%3A+Mar+04/26126649.html Fri, 06 Mar 2026 17:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Press+Releases/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html <p align="justify">OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).</p> <p align="justify">Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), http://www.streetinsider.com/Globe+Newswire/AIM+ImmunoTech+Reminds+Stockholders+of+March+3%2C+2026+Expiration+Date+and+Updates+Terms+of+Previously+Announced+Rights+Offering/26076466.html Fri, 27 Feb 2026 09:00:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html si-local-file:///var/storage/secattach/20260227/26076214.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html Fri, 27 Feb 2026 08:30:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html si-local-file:///var/storage/secattach/20260227/26076214.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html Fri, 27 Feb 2026 08:30:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html si-local-file:///var/storage/secattach/20260227/26076214.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26076214.html Fri, 27 Feb 2026 08:30:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html si-local-file:///var/storage/secattach/20260217/26006811.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html Tue, 17 Feb 2026 08:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html si-local-file:///var/storage/secattach/20260217/26006811.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html Tue, 17 Feb 2026 08:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html si-local-file:///var/storage/secattach/20260217/26006811.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++AIM+ImmunoTech+Inc.++++++++++++++++++/26006811.html Tue, 17 Feb 2026 08:16:00 -0400 AIM AIMI O.00639751 http://www.streetinsider.com/Press+Releases/CORRECTION%3A+AIM+ImmunoTech+Announces+Commencement+of+Rights+Offering/25992645.html <p><em>This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering.</em><br/></p> <p align="justify">OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global http://www.streetinsider.com/Press+Releases/CORRECTION%3A+AIM+ImmunoTech+Announces+Commencement+of+Rights+Offering/25992645.html Thu, 12 Feb 2026 16:35:00 -0400 A.18822917 AIM O.00639751 O.51342642 http://www.streetinsider.com/Press+Releases/CORRECTION%3A+AIM+ImmunoTech+Announces+Commencement+of+Rights+Offering/25992645.html <p><em>This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering.</em><br/></p> <p align="justify">OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global http://www.streetinsider.com/Press+Releases/CORRECTION%3A+AIM+ImmunoTech+Announces+Commencement+of+Rights+Offering/25992645.html Thu, 12 Feb 2026 16:35:00 -0400 A.18822917 AIM O.00639751 O.51342642